Become A Featured Company

FluroTech’s CompleTest™ Makes Cannabis Testing More Accessible

Ryan Allway

February 14th, 2019

Exclusive, News, Top Story

The market for cannabis testing is projected to be $300 million in Canada, $750 million in the United States, and $2.75 billion worldwide. Despite the market size and tremendous need, most cannabis testing solutions are both expensive and unreliable. Cultivators struggle to optimize yields and contain infestations, while consumers have faced recalls for both contamination and mislabeling on a regular basis.

FluroTech Ltd. (TSX-V: TEST) (OTCQB: FLURF) has developed the industry’s most affordable, accurate, portable, and easy-to-use cannabis testing device to solve these problems. After securing final certifications, the device is ready for imminent commercialization, creating an early-stage opportunity for investors.

Cannabis Testing Challenges

Traditional agriculture, food, and beverage industries must adhere to regulations governing everything from crop pesticides to language on labels. Since cannabis remains illegal in many countries, traditional governing bodies can’t exercise control over the production and sales of flower, edibles, oils, and other cannabis derivatives. These dynamics have created significant challenges for governments, cultivators, dispensaries, and consumers.

Even in federally-regulated markets, like Canada, there have been many quality control issues within the cannabis industry. Some products were contaminated with banned pesticides, heavy metals, or mold, while others were mis-labeled with the wrong cannabinoid content information. These problems put consumers at risk of falling ill and cannabis businesses at risk of damaging their brand reputation.

Most cannabis testing equipment is very expensive, making it unaffordable for small cannabis companies. For example, mass spectrometry devices cost upwards of $1 million with a three to 14 day turnaround time for results. High performance chromatography is less expensive at just $250,000 per device and has a much smaller footprint, but it still requires highly-trained operators and takes ten to 14 days to turnaround a single test result.

Please Click here to Download FluroTech Ltd’s Investor Presentation

CompleTest™ Improves Accessibility

FluroTech’s CompleTest™ was designed from the ground up to be the most cost-effective, portable, and easy-to-use solution on the market, providing consistent results in minutes rather than days or weeks. Minimally-trained operators can simply extract a small portion of dried, ground cannabis bud, mix the sample with the test kit reagent, insert the sample into the device, and receive highly-accurate test results on a smartphone or tablet in minutes.

There are many benefits to having these testing capabilities in-house:

*Early Detection: Cultivators can immediately detect early contamination in a grow cycle, purge the grow room, and rapidly return it back to production. In addition, external cannabis supply can be tested before extraction processes.

*Optimization: Cultivators can quickly test different strategies for optimizing harvest time or product quality. For example, growers using CompleTest™ recently found that different lighting solutions improved potency by 50 percent.

It’s difficult to overstate these benefits for cultivators. In Canada, many licensed producers model a one percent increase in potency leading to an additional 80 cents per gram in selling price. A one percent increase in potency in exchange for a $20,000 capital outlay results in a payback period after just 25 kilograms of dried flower. The effect of potency on selling price is amplified even more for cultivators that are focused on extraction end markets.

Commercialization Phase

FluroTech just began to commercialize CompleTest™ in early February after securing Canadian Standards Association (CSA) and Underwriters Laboratories (UL) product safety certification for North America. Prior to the certifications, the company had also showcased the device at the Lift Expo in Vancouver, where it received positive feedback from attendees that could signal early interest in sales of the device.

“We have completed the design verification, testing, and certification of CompleTest™ and are excited to launch into a high growth market,” said FluroTech VP of Business Development Gary Jones. “The CompleTest™ was unveiled to master growers and quality assurance personnel at the recent Lift Expo in Vancouver, where over 60 live demonstrations were completed demonstrating the capabilities of our device.”

Please Click here to Download FluroTech Ltd’s Investor Presentation

The CompleTest™ generates revenue from these sources:

*CompleTest™ Unit: The actual unit sells for $18,000

*CompleTest™ Scopes: Scopes are used to test for THCA/CBDA potency, heavy metals, mold, and banned pesticides. The THCA & CBDA scopes are $6,000 as is the heavy metal scope.

*CompleTest™ Test Kit: Test kits are required for each sample cartridge, providing the necessary reagent for the process. Each test kit costs $60 to $75 with 30 to 50 required per month.

Based on the average cost of each revenue stream, the company would generate with each device sold, $50,000 in the first year and $20,000 per subsequent year per customer. These recurring, high-margin revenue streams resulting from high margin sales exceeding 200 percent in all aspects of the product line could unlock significant value for shareholders over time.

The Bottom Line

FluroTech Ltd. (TSX-V: TEST) (OTCQB: FLURF) represents a near-term opportunity to capitalize on the growing demand for affordable cannabis testing. In addition to these near-term end markets, management’s long-term plans position the company as a front-runner for saliva-based roadside testing, industrial testing, and bio-marking, all of which could add billions more in long-term market potential.

Please Click here to Download FluroTech Ltd’s Investor Presentation

For more information, visit the company’s website 

Disclaimer

The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: https://cannabisfn.com/legal-disclaimer/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Network Partners

Follow Us on Social Media

LinkedIn

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading